Noel Marcus S
Department of Medical Oncology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
J Gastrointest Oncol. 2017 Jun;8(3):449-456. doi: 10.21037/jgo.2017.05.03.
Colorectal cancer is the third most common cancer in the United States and second leading cause of cancer death with over 50,000 patients expected to die from their disease in 2017. For patients who present at diagnosis with advanced disease the standard treatment is systemic chemotherapy. Over the last decade a number of biologic therapies have emerged as viable treatment options for advance colorectal cancer. When these new drugs are combined with chemotherapy survival is prolonged, often without a detriment to quality of life. In this chapter we will review the most active biologic options for treatment of colorectal cancer and place them in the context of a rapidly growing field.
结直肠癌是美国第三大常见癌症,也是癌症死亡的第二大主要原因,预计2017年将有超过5万名患者死于该病。对于诊断时已患有晚期疾病的患者,标准治疗方法是全身化疗。在过去十年中,一些生物疗法已成为晚期结直肠癌可行的治疗选择。当这些新药与化疗联合使用时,生存期会延长,而且通常不会对生活质量造成损害。在本章中,我们将回顾治疗结直肠癌最有效的生物疗法,并将它们置于一个快速发展的领域背景中进行讨论。